Defence Therapeutics Inc.
DTC
CNSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -76.04% | -61.31% | -67.19% | 136.88% | 229.57% |
| Depreciation & Amortization | -22.31% | 130.41% | 405.84% | 256.85% | 554.90% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -76.75% | -64.36% | -63.15% | 70.68% | 106.45% |
| Operating Income | 76.75% | 64.36% | 63.15% | -70.68% | -106.45% |
| Income Before Tax | 74.08% | 73.59% | 70.43% | -56.21% | -89.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 74.08% | 73.38% | 70.20% | -58.48% | -92.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 74.08% | 73.38% | 70.20% | -58.48% | -92.56% |
| EBIT | 76.75% | 64.36% | 63.15% | -70.68% | -106.45% |
| EBITDA | 76.98% | 64.81% | 63.62% | -70.39% | -178.90% |
| EPS Basic | 76.80% | 74.81% | 71.48% | -46.24% | -69.73% |
| Normalized Basic EPS | 76.26% | 74.08% | 71.72% | -44.18% | -67.24% |
| EPS Diluted | 76.80% | 74.81% | 71.48% | -46.24% | -69.73% |
| Normalized Diluted EPS | 76.26% | 74.08% | 71.72% | -44.18% | -67.24% |
| Average Basic Shares Outstanding | 9.86% | 6.05% | 6.96% | 9.85% | 13.67% |
| Average Diluted Shares Outstanding | 9.86% | 6.05% | 6.96% | 9.85% | 13.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |